clinical trial · NCT04492020
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
AbbVie·phase3·completed·n = 518
MigraineUbrogepant 100 mgPlacebo
brief summary
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
started
Aug 21, 2020
primary completion
Apr 19, 2022
completion
Apr 19, 2022
last updated
May 31, 2023
official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol